New hope for tough pancreatic cancer? early trial tests combo therapy
NCT ID NCT06981806
Summary
This is an early safety study for people with advanced pancreatic cancer that has spread and stopped responding to standard chemotherapy. It will test a combination of two drugs, cosibelimab and balixafortide, to find the safest dose and see if the treatment is tolerable. The main goal is to understand side effects, but researchers will also look for any signs that the treatment might help slow the cancer.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for METASTATIC PANCREATIC DUCTAL ADENOCARCINOMA are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Cedars-Sinai Cancer at SOCC
Los Angeles, California, 90048, United States
Conditions
Explore the condition pages connected to this study.